Selank is a synthetic tuftsin analog out of the Russian Academy of Sciences. Mechanism, half-life, and what the Western corpus does and doesn't say. RUO.
If you've read three peptide newsletters this month, you've seen Selank framed as the "anxiolytic without sedation" peptide. That framing isn't wrong. It's also not the literature. The literature is mostly Russian, mostly small, and mostly invisible to PubMed's English-first indexing. This page is the assembled picture before you read anyone's stack post.
For research use only. Not medical advice. Nothing here is a recommendation to administer, prescribe, or self-administer any compound.
Selank. A synthetic heptapeptide. Specifically, a stabilized analog of tuftsin — a four-amino-acid immunomodulatory peptide fragment of the heavy chain of immunoglobulin G — with a tripeptide tail (Pro-Gly-Pro) added to the C-terminus to extend half-life.
Mechanism class: anxiolytic and immunomodulatory research peptide. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the late 1990s and registered for clinical use in Russia. Not approved in the US. Not approved in the EU.
The category Selank lives in inside this newsletter: cognition and stress-axis research peptides, alongside Semax and Cerebrolysin.
Selank's parent molecule, tuftsin, was identified in the 1970s as a phagocytosis-stimulating fragment of IgG. The Russian program took that immunomodulatory backbone and appended Pro-Gly-Pro to slow enzymatic degradation, then characterized the molecule across CNS rather than purely immune endpoints.
The mechanism story in the published Russian work is layered. Selank appears to modulate GABAergic tone without binding the benzodiazepine site directly — the anxiolytic effect doesn't recapitulate the sedation, tolerance, or withdrawal profile of benzodiazepines. There's also work on monoaminergic systems (serotonin and dopamine turnover) and on BDNF and enkephalin gene expression in rodent hippocampus and hypothalamus.
The one-line summary the literature supports: an anxiolytic-class peptide that appears to reach the CNS via intranasal delivery and affect stress-response signaling without the GABA-A direct-agonist liability profile.
The one-line summary the literature does not support: any specific clinical claim outside the Russian registration scope.
Half-life. Short in plasma — minutes for the parent peptide. The Pro-Gly-Pro tail extends stability versus native tuftsin but doesn't make Selank a long-acting molecule. Effects in the published behavioral work appear to outlast plasma clearance, which is consistent with a peptide that acts upstream of receptor-system changes rather than as a direct sustained agonist.
Route. Intranasal is the dominant administered route in the Russian clinical and preclinical corpus. This is the route Selank was registered under. Subcutaneous injection appears in some research contexts. Oral administration is not characterized in the published work — peptides of this class are degraded by digestive enzymes, and Selank is no exception in the in-vitro work that exists.
This is the part most stack posts skip.
The Selank literature is heavily Russian-language, published primarily in journals indexed in Russian databases and only partially mirrored to PubMed. The foundational authors are at the Institute of Molecular Genetics, Russian Academy of Sciences. Key program names: Myasoedov, Andreeva, Kozlovskaya, Semenova.
What you can find in English on PubMed:
What you cannot easily find in English:
In the tier framework this newsletter uses:
The honest framing: Selank has a real corpus. That corpus is real Russian academic work. It is not a robust Western clinical evidence base. Treat both facts as true.
Field reports from the founder-biohacker cohort tend to cluster around three things.
Anxiolysis without sedation. The most common reported subjective change. Users describe a "ceiling lowered on baseline anxiety" effect rather than the cognitive blunting of benzodiazepines. Onset is typically reported within the first few intranasal administrations.
Cognition under load. Reports of better task focus during high-stress periods — investor meetings, board prep, deadline weeks. This is consistent with the Russian behavioral literature on stress-resistance endpoints in rodents but should not be confused with proof of cognitive enhancement in healthy humans.
Stack pairing. Most often reported alongside Semax — same Russian Academy program, same intranasal route, complementary endpoint coverage. The "Selank–Semax pair" is the single most common founder-operator stack mention for cognition and stress.
None of this is a recommendation. Founder N=1 reports are signal, not proof.
A lot.
If anyone tells you the Selank evidence is "settled," they haven't read the corpus.
Selank is one of fourteen compounds covered in The 2026 Peptide Stack Map — the lead magnet you can pull down at the link below. Mechanism, half-life, and literature pointers for each compound on one page.
The Compound's Sunday issues cover Selank in the context of the cognition-and-stress cluster: Selank, Semax, Cerebrolysin, and the broader Russian Academy of Sciences peptide program. Issue 1 is the entry point. We'll continue the cognition cluster across the first quarter of issues, and we go behind the email gate for the dose-citation work — which is where dosing belongs.
If you want the weekly briefing on what's new, what survived peer review this week, and what's worth the vial, subscribe.
Disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full FTC disclosure on the About page. For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
Subscribe to The Compound — the Sunday briefing on peptides for founder-operators. One email a week. Pull down the Stack Map on signup.
14 compounds, half-lives, and the literature — one PDF.
Download the PDF →